Patients on immunosuppressive therapy have an increased risk of infections. Since infections have a potential to trigger acute porphyric attacks vigilance is motivated regarding signs or symptoms of infection and/or possible symptoms of a porphyric attack.

Infections are common in patients using immunosuppressants and since infections might trigger an acute porphyric attack, vigilance regarding signs and symptoms of an infection and/ or a porphyric attack is recommended.

Antibody preparation with no CYP metabolism. Based on the pharmacokinetics, Anakinra is not expected to have any porphyrinogenic effects.

Human interleukin 1 receptor antagonist produced in Escherichia coli cells by recombinant DNA technology.

Anakinra is used in the treatment of rheumatoid arthritis as monotherapy or in combination with methotrexate in patients with an inadequate response to methotrexate alone. It is administered as a subcutaneous injection.

Anakinra is not metabolised by the liver via phase 1 mechanisms and is not known to inhibit cytochrome P450 enzymes. The metabolism of anakinra is expected to be similar as for endogenous antibodies, which are metabolised to peptides and amino acids in various body tissues and in plasma by circulating phagocytic cells or by their target antigen-containing cells.